King's College London

Research portal

UPDATED S2K GUIDELINES ON THE MANAGEMENT OF PEMPHIGUS VULGARIS AND FOLIACEUS INITIATED BY THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV)

Research output: Contribution to journalArticlepeer-review

Pascal Joly, Barbara Horwath Horwath, Katerina Patsatsi , Soner Uzun, Rikke Bech, Stefan Beissert, Reuven Bergman, Philippe Bernard, Luca Borradori, Marzia Caproni , Frédéric Caux, Giuseppe Cianchini, Maryam Daneshpazhooh, De Dipankar, Marian Dmochowski, Kossara Drenovska, Jan Ehrchen, Claudio Feliciani, Matthias Goebeler, Richard Groves & 23 more Claudia Guenther, Silke Hofmann, Dimitrios Ioannides, Cezary Kowalewski, Ralf Ludwig, Yen Loo Lim, Branka Marinovic, Angelo Valerio Marzano, José M. Mascaró, Daniel Mimouni, Dedee F Murrel, Carlo Pincelli, Catherine Prost Squarcioni , Miklós Sárdy, Jane Setterfield, Eli Sprecher, Snejina Vassileva, Katarzyna Wozniak, Savas Yayli , Giovanna Zambruno, Detlef Zillikens , Michael Hertl , Enno Schmid

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Accepted/In press10 Jul 2020

King's Authors

Abstract

Abstract:
Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the USA.
Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus.
Results: The guidelines for the management of pemphigus were updated and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organisations.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454